CD19-targeted chimeric antigen receptor T-cell(Pell Bio-Med Technology)

CD19靶向嵌合抗原受体T细胞（沛尔生技）

Report date: 2024/05/10 20:00:07

Base Information

Drug NameCD19-targeted chimeric antigen receptor T-cell(Pell Bio-Med Technology)

Drug Alias NameCD19 CAR-T(Pell Bio-Med Technology)PL-001

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsPrimary mediastinal B cell lymphomaLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryTaiwan

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesPell Bio-Med Technology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesPell Bio-Med Technology Co Ltd

Inactive CompaniesN/A

Active IndicationsPrimary mediastinal B cell lymphomaLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[4]

Inactive IndicationsN/A

Other Information

ATC CodeN/A